<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Form 8-K - Current report</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Form 8-K - Current report</h1>

    <table>
      <tr><th>Ticker</th><td>UPB</td></tr>
      <tr><th>Float</th><td>25.5 M</td></tr>
      <tr><th>IO</th><td>62.27%</td></tr>
      <tr><th>MC</th><td>784 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Upstream Bio, Inc. (CIK: 0002022626) filed a Form 8-K dated February 11, 2026 reporting Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits). The filing includes an HTML primary document (d103888d8k.htm) available at https://www.sec.gov/Archives/edgar/data/2022626/000119312526045649/d103888d8k.htm and an exhibit (EX-99.1) consisting of a press release and accompanying graphics. The exhibit set and XBRL taxonomy/instance files are included in the submission. The 8-K conveys current company disclosures and attaches the press release (EX-99.1) that announces top-line clinical results (see EX-99.1 in the filing).</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Company filed a current report (Form 8-K) disclosing results and issuing a press release (EX-99.1), ensuring investors have timely disclosure.</li><li>Includes Regulation FD disclosure, indicating broad dissemination of material information.</li><li>Primary filing and exhibits (HTML and XBRL files) are available on the SEC EDGAR site for review.</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>The 8-K index does not provide detailed numeric financial impact or complete financial statements within the index itself.</li><li>No ownership/beneficial ownership changes (e.g., Schedule 13 filings) are reported in this filing.</li><li>Investors must open the attached press release (EX-99.1) to see full clinical details and implications; summary in the index is limited.</li></ul>
    </div>

    <div class="section">
      <a href="https://www.sec.gov/Archives/edgar/data/2022626/000119312526045649/0001193125-26-045649-index.htm" target="_blank">Original Article</a>
    </div>

    <div class="small">UPB â€¢ TradersLink AI News</div>
  </div>
</body>
</html>